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Abstract
Background: Ultraviolet A1 (340–400 nm, UVA1) phototherapy is highly effective in sclerotic
lesions of systemic sclerosis (SSc). Histological evaluation of skin specimens obtained before and
after UVA1 phototherapy revealed loosening of collagen bundles and the appearance of small
collagen fibers. We have previously shown that UVA1 irradiation induced collagenase in vitro study
by using SSc fibroblasts. The increased levels of mRNA and protein of decorin in SSc fibroblasts
were reported. In this study, we focus on the lesional expression of small dermatan sulfate
proteoglycan, decorin that has a role of binding to collagen and fibrillogenesis.
Case presentation: We employed immunohistochemical analysis of decorin before and after
UVA1 phototherapy. The skin specimens from three patients who were effectively treated with
UVA1 phototherapy were analysed. Monoclonal antibody 6B6 as the specific reactivity to decorin
was used. The increased decorin was focally accumulated in the newly synthesized collagen fibers
in the sclerotic lesion of SSc. After UVA1 phototherapy, decorin was decreased in upper to middle
dermis, although decorin was slightly increased in papillary dermis.
Conclusions: These results suggest that decreased and normalized levels of accumulated decorin
may relate to the efficacy of sclerotic lesions in UVA1 phototherapy.
Background
Decorin is a leucine-rich proteoglycan (PG) with a protein
core of 36 kDa and a glycosaminoglycan (GAG) chain at-
tached to the N-terminus [1]. Decorin contributes to fibril
stability of several collagen types in vivo, including types
I, II, V, VI and XIV by binding through leucine-rich repeat
regions or GAG chain [2], and influences cell adhesion by
interacting with extracellular adhesive molecules such as
fibronectin [3] and thrombospondin [4]. In some cells,
decorin activates the epidermal growth factor receptor,
thereby triggering a signaling cascade that leads to phos-
phorylation of mitogen-activated protein kinases, to the
induction of p21, and to growth suppression [5]. Decorin
also interacts with transforming growth factor (TGF)-β
and modulates its activity and transfection of decorin
gene prevent fibrosis in kidney [6], or it may increase TGF-
β activity on osteoblasts [7].
SSc is a connective tissue disease characterized by fibrosis
of the skin, subcutaneous tissue, and various internal or-
gans. The most prominent pathological manifestation of
the disease is an abnormal accumulation of extracellular
matrix molecules, especially type I and III collagen [8,9].
Decorin binds to type I collagen and regulates
Published: 12 March 2003
BMC Dermatology 2003, 3:2
Received: 12 December 2002
Accepted: 12 March 2003
This article is available from: http://www.biomedcentral.com/1471-5945/3/2
© 2003 Sawada et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Page 1 of 4
(page number not for citation purposes)
BMC Dermatology 2003, 3 http://www.biomedcentral.com/1471-5945/3/2fibrillogenesis, and mRNA of decorin from fibroblast of
patients with SSc were previously examined. Decorin
mRNA with early stage SSc (less than 1 year duration of
disease) was highly expressed than that of normal control
[9].
SSc is an autoimmune disorder characterized by excessive
deposition of collagen within the skin and other organs.
SSc can severely affect the quality of life and may cause sig-
nificant morbidity. Numerous treatments have been tried
but with only limited success. UVA1 phototherapy has
proven to be effective for atopic dermatitis [10], cutane-
ous T cell lymphoma [11], and urticaria pigmentosa [12]
because it depletes skin-infiltrating T cells or mast cells.
More recently, UVA1 has been shown to clear sclerosis
plaques in patients with long-standing widespread mor-
phea, resistant to previous treatments [13,14] and to be ef-
fective for scleroderma in patients with SSc [15]. UVA1 is
also effective to other sclerotic disorders such as localized
scleroderma [16] and lichen sclerosus even with low dose
regimen [17]. We have previously shown that UVA1 pho-
totherapy treated skin lesions were markedly softened af-
ter 9–29 exposures in all the SSc patients studied [15].
Clinical improvement was associated with an increase in
joint passive range of motion values, skin temperature,
and cutaneous elasticity. Histological evaluation of skin
specimens obtained before and after UVA1 phototherapy
revealed loosening of collagen bundles and the appear-
ance of small collagen fibers. Moreover, we have shown
that UVA1 irradiation induced collagenase in vitro study
by using SSc fibroblasts [[18] in press]. In this study, we
analysed the skin specimen of previous study in which
UVA1 phototherapy was highly effective to examine a
small dermatan sulfate proteoglycan, decorin that has a
role of binding to collagen and fibrillogenesis.
Case Presentation
Patients
Two diffuse type (2 female) and one limited type (1 fe-
male) patients with SSc were treated with UVA1 photo-
therapy after informed consent had been obtained. The
patients' profiles are summarized in detail in Table 1 (see
additional file 1). Three patients enrolled in this study
were identical to those of the previous report [15].
UVA1 Phototherapy
For UVA1 irradiation, a partial body UVA1 Sellamed 2000
System Dr Sellmaier (Sellas, Gevelsberg, Germany) irradi-
ation device was used as previously described [15]. The
emission was filtered with a UVA1 filter (Sellas) and an in-
frared absorbing filter UG1 (Schott, Mainz, Germany) and
consisted exclusively of UV wavelength greater than 340
nm and smaller than 450 nm. The UVA1 irradiance was
measured with a IL 1700 photometer (International Light,
Newburyport, Mass) and found to be 50 mW/cm2 at body
distance [19]. To rule out sensitivity to UVA1 irradiation,
all patients were phototested before UVA1 phototherapy
with increasing doses of UVA1 radiation (10–60 J/cm2) as
previously described [15]. For UVA1 phototherapy, all pa-
tients were treated with the lesional forearm and hand to
single doses of 60 J/cm2 UVA1 daily (Monday-Friday).
UVA1 phototherapy was given as monotherapy except for
the oral medication which the patients had been given be-
fore a phototherapy session. Topical treatment was re-
stricted to the use of emollients.
Immunohistochemical analysis of Decorin
6B6 is a monoclonal antibody prepared with a purified
small dermatan sulfate PG from human ovarian fibroma
capsule as an antigen [20]. Its epitope region located with-
in a stretch of amino acid residues 50–65, termed the N-
terminal cysteine cluster region, and is useful for immu-
nohistochemistry [21].
Biopsy specimens taken from three patients before and at
the end point of treatment and three normal skin taken
from margin of benign tumor were fixed with 10% buff-
ered formalin for 48 h, followed by embedding in paraf-
fin. Tissue sections (3 µm) were dewaxed in xylene, and
rehydrated through decreasing concentrations of ethanol.
To block endogenous peroxidase activity, rehydrated sec-
tions were treated in a 0.3 % H2O2 in absolute ethanol for
5 min, and were processed for immunostaining with 6B6
(Seikagaku Kogyo, Tokyo, Japan, 500-fold dilution) and a
Histofine Simple Stain Max PO (M) (Nichirei, Tokyo, Ja-
pan) according to a manufacturer's instruction. For regu-
lar histology tissue sections were stained with Elastica van
Gieson stain.
Site-matched biopsy specimens were taken from the fore-
arms of patients before and after UVA1 phototherapy. The
histopathology revealed that there were enlarged collagen
bundles in the dermis before therapy. After UVA1 irradia-
tion, histological analysis showed a loosening of collagen
bundles, the appearance of small collagen fibers in the
dermis and a decrease in the thickness of the dermal col-
lagen (Fig. 1). In normal skin, three specimens were
stained similarly and decorin localized entire dermis co-
distributing with collagen fiber, but epidermis, dermal re-
gion facing the basement membrane, and appendage was
not stained (Fig. 2G). In SSc patients, decorin was stained
entire dermis, especially focally accumulated collagen
bundles in upper to middle dermis. Decorin shows re-
markable decrease around enlarged collagen bundles in
upper to middle dermis according to depth that UVA1
achieve after UVA1 phototherapy, However, decorin was
slightly increased around increased small collagen fibers
in papillary dermis (Fig. 2A,2B,2C,2D,2E,2F).Page 2 of 4
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ers by UVA1-induced matrix metalloproteinase may lead
to decrease accumulated decorin in the upper to middle
dermis and normalization of decorin may induce normal
collagen assembly. This sequence may soften the skin of
SSc.
Conclusions
In this study, aberrant localization of decorin was normal-
ized after UVA1 phototherapy. The altered expression of
decorin may correlate with the change of collagen fiber.
These results suggest that decreased and normalized levels
of accumulated decorin may relate to the efficacy of scle-
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Figure 1
Histological evaluation of site-matched skin biopsy 
specimens before (A, C, E) and after (B, D, F) UVA1 
phototherapy Biopsy specimens were taken from sclerotic 
skin lesions of the forearms of patients 1 (A, B), 2 (C, D), and 
3 (E, F). Before UVA1 therapy, there are enlarged collagen 
bundles in the dermis. After UVA1 irradiation, histological 
analysis shows a loosening of collagen bundles, the appear-
ance of small collagen fibers in the dermis and a decrease in 
the thickness of the dermal collagen. (Elastica van Gieson 
stain, original magnification × 200)
Figure 2
Immunohistochemical analysis of decorin of site-
matched skin biopsy specimens before (A, C, E) and 
after (B, D, F) UVA1 phototherapy Biopsy specimens 
were taken from sclerotic skin lesions of the forearms of 
patients 1 (A, B), 2 (C, D), and 3 (E, F), and were stained with 
monoclonal antibody 6B6 that recognize core protein of 
small dermatan sulfate proteoglycan, decorin. Decorin is 
decreased in upper to middle dermis and enlarged collagen 
bundles are disappeared after UVA1 phototherapy. Decorin 
is slightly increased in papillary dermis, suggesting newly syn-
thesized collagen. In normal skin (G), decorin is stained 
entire dermis, but epidermis, dermal region facing the base-
ment membrane, and appendage are not stained.Page 3 of 4
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